| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC.
|
J Exp Med
|
2010
|
2.26
|
|
2
|
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
|
Vaccine
|
2005
|
1.94
|
|
3
|
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection.
|
J Clin Invest
|
2008
|
1.74
|
|
4
|
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
|
Vaccine
|
2007
|
1.67
|
|
5
|
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
|
Vaccine
|
2009
|
1.36
|
|
6
|
Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.
|
J Gen Virol
|
2007
|
1.29
|
|
7
|
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
|
Antivir Ther
|
2005
|
1.22
|
|
8
|
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.
|
Vaccine
|
2009
|
1.06
|
|
9
|
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
|
J Infect Dis
|
2012
|
1.06
|
|
10
|
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
|
Cancer Immunol Immunother
|
2004
|
1.03
|
|
11
|
Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
|
J Gen Virol
|
2003
|
0.98
|
|
12
|
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
|
Clin Cancer Res
|
2004
|
0.95
|
|
13
|
The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.
|
J Virol
|
2011
|
0.89
|
|
14
|
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
|
Vaccine
|
2013
|
0.89
|
|
15
|
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
|
J Virol
|
2010
|
0.89
|
|
16
|
Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice.
|
J Immunol
|
2004
|
0.89
|
|
17
|
Fasciola hepatica cathepsin L suppresses sheep lymphocyte proliferation in vitro and modulates surface CD4 expression on human and ovine T cells.
|
Parasite Immunol
|
2002
|
0.87
|
|
18
|
A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?
|
Proc Natl Acad Sci U S A
|
2010
|
0.85
|
|
19
|
Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias.
|
J Immunol
|
2003
|
0.85
|
|
20
|
Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.
|
PLoS One
|
2010
|
0.82
|
|
21
|
Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.
|
J Virol
|
2010
|
0.82
|
|
22
|
Genetic stability of recombinant MVA-BN.
|
Vaccine
|
2005
|
0.79
|
|
23
|
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
|
Hum Gene Ther
|
2003
|
0.79
|
|
24
|
Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides.
|
J Immunol
|
2003
|
0.79
|
|
25
|
Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity.
|
Front Immunol
|
2013
|
0.79
|
|
26
|
A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.
|
PLoS One
|
2013
|
0.78
|
|
27
|
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
|
PLoS One
|
2015
|
0.75
|